As to relationships among ZBTB46, AR signaling, and NEPC progression, we checked expression levels of ZBTB46, neuroendocrine markers (chromogranin A/B (CHGA/B) and enolase 2 (ENO2)), and androgen-responsive genes (kallikrein-3 (KLK3) and NK3 homeobox 1 (NKX3-1)) in an RNA-sequence (RNA-Seq) dataset (GSE48403) in paired prostate cancer samples pre-ADT and post-ADT. The gene discussed is ENO2; the disease is prostate carcinoma.